Episode

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Podcast: The Long Run with Luke Timmerman
Published: Mar 3, 2026
Duration seconds: 3945
Processing state: not_requested
Canonical source: https://soundcloud.com/longrunpodcast/ep195-ken-song-on-t-cell
Audio: https://feeds.soundcloud.com/stream/2276762408-longrunpodcast-ep195-ken-song-on-t-cell.mp3
JSON: /v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep195-ken-song-on-t-cell-engagers-for-autoimmune-diseases
Markdown: /podcast/the-long-run-with-luke-timmerman-1124799/ep195-ken-song-on-t-cell-engagers-for-autoimmune-diseases.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep195-ken-song-on-t-cell-engagers-for-autoimmune-diseases/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-long-run-with-luke-timmerman-1124799/ep195-ken-song-on-t-cell-engagers-for-autoimmune-diseases.md
Read the agent-friendly Markdown representation of this episode resource.

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.